|
August 3-5, 2009
(August 3-4 main conference, August 5 post-conference workshop*)
Practical Strategies Generating Exciting Preclinical and Clinical Results
As the race continues to discover and develop the next generation of antibody drugs, new approaches are emerging to improve antibody efficacy and potency by conjugating antibodies with drugs, cytotoxins and other agents. Numerous studies are also underway to evaluate combinations of antibodies to improve disease treatment. This is the only antibody conference on the market to bring together all of the leading companies in the field of antibody conjugation to share their latest preclinical/clinical results, and to feature emerging data on multiple antibody combinations projects. Covering antibody drugs for both oncology and non-oncology indications, this event will also provide practical strategies for developing dual and multi-targeted antibody drugs and examples of using pharmacodynamic biomarkers to inform antibody dosing strategies.
Why You Should Attend:
- Hear preclinical and clinical data from multiple antibody development projects
- Meet all of the leading companies who are innovating in the field of antibody conjugation
- Discover emerging trends in antibody technology development and biomarkers for antibody drugs
Confirmed Speakers and Sessions
(As of March 10, 2009)
Antibody-Drug Conjugates and Other Conjugation Strategies
- Paul Polakis, Ph.D., Director, Cancer Targets, Genentech. Inc.
- Vincent de Groot, Ph.D., Chief Executive Officer, Syntarga B.V., The Netherlands
- Aya Jakobovits, Ph.D., Executive Vice President and Head, Research and Development Agensys, Inc.
- William C. Olson, Ph.D., Senior Vice President, R&D, Progenics Pharmaceuticals, Inc.
- S.V. Govindan, Ph.D., Senior Director, Conjugation, Immunomedics, Inc.
- Michele Sanicola-Nadel, Ph.D., Associate Director, Tumor Cell Growth and Adhesion, Discovery Oncology, Biogen Idec
- Erik R Vandendries, M.D., Ph.D., Associate Director, Clinical Research and Development, Hematology Medical Research, Wyeth Research
- Nils Lonberg, Ph.D., Senior Vice President, Scientific Director, Medarex
- John M. Lambert, Ph.D., Executive Vice President and Chief Scientific Officer, ImmunoGen, Inc.
- Jonathan Drachman, M.D., Vice President Translational Medicine, Seattle Genetics, Inc.
- Barbara Klencke, M.D., Group Medical Director, Genentech, Inc.
- Ronit Simantov, M.D., Chief Medical Officer, CuraGen Corporation
Approaches to Improve Antibody Efficacy and Potency
- Sanjay D. Khare, Ph.D., President, R&D, ImmunGene, Inc.
- John R. Desjarlais, Ph.D., Vice President, Research, Xencor, Inc.
- Frank Calzone, Ph.D., Executive Scientific Director, Oncology Research, Amgen, Inc.
- Alison Humbles, Ph.D., Senior Scientist, Department of Respiratory, Inflammation and Autoimmunity, Medimmune, LLC
- Tobias Raum, Ph.D., Senior Director Lead Discovery, Human Antibody Technologies, Micromet AG, Germany
Bispecific and Multispecific Antibody Drugs
- Charlotte McDonagh, Ph.D., Associate Director, Merrimack Pharmaceuticals, Inc.
- Tariq Ghayur, Ph.D., Senior Principal Scientist & Research Fellow, Abbott Bioresearch Center
- Robert Mabry, Ph.D., Senior Scientist, Department of Protein Engineering, ZymoGenetics, Inc.
Combinations of Antibody Therapies
- Mark Pegram, M.D., Professor, University of Miami
- David M. Goldenberg, ScD, MD; Founder and Chairman, Immunomedics, Inc.
Pharmacodynamic Biomarkers in Antibody Development
- Antonio Gualberto, M.D., Ph.D., Director and Global Clinical Leader, Oncology, Pfizer Global R&D
- Barbara White, M.D., Vice President of Clinical Development, Medimmune
Post-Conference Workshop: Understanding and Exploiting The Role of Cancer Stem Cells in Drug Development
- Timothy Hoey, Ph.D., Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.
- Jeff Jackson, Ph.D., Director, Cancer Stem Cell DPU, Oncology R&D, GlaxoSmithKline
- Jenny P. Mather, M.D., Ph.D., Senior Vice President, Cancer Stem Cell Research, MacroGenics, Inc. West
- Ivan Bergstein, M.D., CEO, Stemline Therapeutics, Inc.
- Chia Portera, M.D., Ph.D., Assistant Medical Director, Exploratory Clinical Development, Genentech BioOncology
- Lyuba Varticovski, Staff Clinician, National Cancer Institute
Scientific Advisory Board
Ulrik Nielsen, Ph.D., Senior Vice President, Research, Merrimack Pharmaceuticals
Zhenping Zhu, M.D., Ph.D., Vice President, Antibody Technology, ImClone Systems
William Dall'Acqua, Ph.D., Director, R&D, MedImmune, Inc.
Nils Lonberg, Ph.D., Senior Vice President and Scientific Director, Medarex, Inc.
Taruna Arora, Ph.D., Principal Scientist, Antibody Research, Amgen, Inc.
|
